The role of daidzein-loaded sterically stabilized solid lipid nanoparticles in therapy for cardio-cerebrovascular diseases

Biomaterials

Volumn 29, Issue 30, 2008, Pages 4129-4136

  Gao, Yu ^a   Gu, Wangwen ^a   Chen, Lingli ^a   Xu, Zhenghong ^a   Li, Yaping ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Cardiovascular disease; Cerebrovascular diseases; Daidzein; Nanoparticles

Indexed keywords

ABSORPTION; BIOCHEMISTRY; BLOOD VESSELS; BODY FLUIDS; CARDIOVASCULAR SYSTEM; DRUG PRODUCTS; HEMODYNAMICS; HOMOGENIZATION METHOD; NANOPARTICLES; NANOSTRUCTURED MATERIALS; NANOSTRUCTURES; NONMETALS; OCCUPATIONAL RISKS; OXYGEN; PHOSPHOLIPIDS; SUSPENSIONS (COMPONENTS);

BOVINE SERUM ALBUMIN; CARDIOVASCULAR DISEASE; CEREBRAL BLOOD FLOW; CEREBROVASCULAR DISEASES; CIRCULATION TIME; CORONARY RESISTANCE; DAIDZEIN; ENTRAPMENT EFFICIENCY; IN VITRO RELEASES; ISCHEMIA-REPERFUSION INJURY; MEAN PARTICLE SIZE; ORAL ABSORPTION; OXYGEN CONSUMPTIONS; PROTECTIVE EFFECT; SOLID LIPID NANOPARTICLES; SUSTAINED RELEASE;

HEALTH;

ALBUMIN; DAIDZEIN; SOLID LIPID NANOPARTICLE;

ANIMAL MODEL; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; CORONARY VASCULAR RESISTANCE; DRUG DELIVERY SYSTEM; HEART MUSCLE OXYGEN CONSUMPTION; IN VITRO STUDY; ISCHEMIA; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BLOOD FLOW VELOCITY; BRAIN ISCHEMIA; DOGS; DRUG CARRIERS; ISOFLAVONES; LIPIDS; MALE; NANOPARTICLES; PHYTOESTROGENS; RATS; RATS, SPRAGUE-DAWLEY;

BOVINAE; CANIS FAMILIARIS; RATTUS;

EID: 49449102923     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2008.07.008     Document Type: Article

References (29)

1. Eisenberg M.J., Brox A., and Bestawros A.N. Calcium channel blockers: an update. Am J Med 116 (2004) 35-43
2. Boumendil E.F., and Mugnier C. Risk of cardio-cerebrovascular accidents associated with nitrates and other cardiovascular drugs. Am J Hypertens 13 Suppl 1 (2000) S264-S265
3. Murkies A.L., Wilcox G., and Davis S.R. Clinical review 92: phytoestrogens. J Clin Endocrinol Metab 83 (1998) 297-303
4. Wang H.Z., Zhang Y., Xie L.P., Yu X.Y., and Zhang R.Q. Effects of genistein and daidzein on the cell growth, cell cycle, and differentiation of human and murine melanoma cells. J Nutr Biochem 13 (2002) 421-426
5. Lo F.H., Mak N.K., and Leung K.N. Studies on the anti-tumor activities of the soy isoflavone daidzein on murine neuroblastoma cells. Biomed Pharmacother 61 (2007) 591-595
6. Choi M.S., Jung U.J., Yeo J., Kim M.J., and Lee M.K. Genistein and daidzein prevent diabetes onset by elevating insulin level and altering hepatic gluconeogenic and lipogenic enzyme activities in non-obese diabetic (NOD) mice. Diabetes Metab Res Rev 24 (2008) 74-81
7. Jia T.L., Wang H.Z., Xie L.P., and Zhang R.Q. Daidzein enhances osteoblast growth that may be mediated by increased bone morphogenetic protein (BMP) production. Biochem Pharmacol 65 (2003) 709-715
8. Li M., Poon P., and Woo J. A pilot study of phytoestrogen content of soy foods and traditional Chinese medicines for women's health in Hong Kong. Int J Food Sci Nutr 55 (2004) 201-205
9. Kurzer M.S., and Xu X. Dietary phytoestrogens. Annu Rev Nutr 17 (1997) 353-381
10. Rimbach G., Boesch-Saadatmandi C., Frank J., Fuchs D., Wenzel U., Daniel H., et al. Dietary isoflavones in the prevention of cardiovascular disease - a molecular perspective. Food Chem Toxicol 46 (2008) 1308-1319
11. Kulling S.E., Honig D.M., and Metzler M. Oxidative metabolism of the soy isoflavones daidzein and genistein in vitro and in vivo. J Agric Food Chem 49 (2001) 3024-3033
12. Müller R.H., Mäder K., and Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm 50 (2000) 161-177
13. Blasi P., Giovagnoli S., Schoubben A., Ricci M., and Rossi C. Solid lipid nanoparticles for targeted brain drug delivery. Adv Drug Deliv Rev 59 (2007) 454-477
14. Zur Mühlen A., Schwarz C., and Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery - Drug release and release mechanism. Eur J Pharm Biopharm 45 (1998) 149-155
15. Janning P., Schuhmacher U.S., Upmeier A., Diel P., Michna H., Degen G.H., et al. Toxicokinetics of the phytoestrogen daidzein in female DA/Han rats. Arch Toxicol 74 (2000) 421-430
16. Longa E.Z., Weinstein P.R., Carlson S., and Cummins R. Reversible middle cerebral artery occlusion without craniectomy in the rats. Stroke 20 (1989) 84-91
17. Müller R.H., Jacobs C., and Kayser O. Nanosuspensions as particulate drug formulations in therapy: rationale for development and what we can expect for the future. Adv Drug Deliv Rev 47 (2001) 3-19
18. Qiu F., Chen X., Song B., Zhong D., and Liu C. Influence of dosage forms on pharmacokinetics of daidzein and its main metabolite daidzein-7-O-glucuronide in rats. Acta Pharmacol Sinica 26 (2005) 1145-1152
19. Li Y.P., Pei Y.Y., Zhou Z.H., Zhang X.Y., Gu Z.H., Ding J., et al. Stealth polycyanoacrylate nanoparticles as tumor necrosis factor-alpha carriers: pharmacokinetics and anti-tumor effect. Biol Pharm Bull 24 (2001) 662-665
20. Li Y.P., Pei Y.Y., Zhang X.Y., Gu Z.H., Zhou Z.H., Yuan W.F., et al. PEGylated PLGA nanoparticles as protein carriers: synthesis, preparation and in vivo biodistribution in rats. J Controlled Release 71 (2001) 203-211
21. Agnisola C. Role of nitric oxide in the control of coronary resistance in teleosts. Comp Biochem Physiol A Mol Integr Physiol 142 (2005) 178-187
22. Bandera E., Botteri M., Minelli C., Sutton A., Abrams K.R., and Latronico N. Cerebral blood flow threshold of ischemic penumbra and infarct core in acute ischemic stroke: a systematic review. Stroke 37 (2006) 1334-1339
23. Müller R.H., Rühl D., and Runge S.A. Biodegradation of solid lipid nanoparticles as a function of lipase incubation time. Int J Pharm 144 (1996) 115-121
24. Willigers H.M., Prinzen F.W., and Roekaerts P.M. Comparison of the effects of dexmedetomidine and esmolol on myocardial oxygen consumption in dogs. Eur J Anaesthesiol 21 (2004) 957-966
25. Gerber B.L., Wijns W., Vanoverschelde J.L., Heyndrickx G.R., De Bruyne B., Bartunek J., et al. Myocardial perfusion and oxygen consumption in reperfused noninfarcted dysfunctional myocardium after unstable angina: direct evidence for myocardial stunning in humans. J Am Coil Cardiol 34 (1999) 1939-1946
26. Ge Y.B., Chen D.W., Xie L.P., and Zhang R.Q. Optimized preparation of daidzein-loaded chitosan microspheres and in vivo evaluation after intramuscular injection in rats. Int J Pharm 338 (2007) 142-151
27. Imai H., Masayasu H., Dewar D., Graham D.I., and Macrae I.M. Ebselen protects both gray and white matter in a rodent model of focal cerebral ischemia. Stroke 32 (2001) 2149-2154
28. Yrjänheikki J., Tikka T., Keinänen R., Goldsteins G., Chan P.H., and Koistinaho J. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci USA 96 (1999) 13496-13500
29. Sinha J., Das N., and Basu M.K. Liposomal antioxidants in combating ischemia-reperfusion injury in rat brain. Biochem Pharmacol 55 (2001) 264-271